Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term Follow-up Study to Evaluate the Safety of Repeated Intra-Articular Injection of SI-613 in Patients with Osteoarthritis.

Trial Profile

Long Term Follow-up Study to Evaluate the Safety of Repeated Intra-Articular Injection of SI-613 in Patients with Osteoarthritis.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac-Eatlhyaluronate (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Ono Pharmaceutical; Seikagaku Corporation
  • Most Recent Events

    • 23 Mar 2021 According to an Ono Pharmaceutical media release, Seikagaku has obtained from the Ministry of Health, Labour and Welfare (MHLW) a manufacturing and marketing approval in Japan for JOYCLU 30mg Intra-articular Injection (diclofenac etalhyaluronate sodium; JOYCLU) for the indication of osteoarthritis (knee joint and hip joint).The approval is based on the results of three Phase III clinical studies conducted in Japan (JapicCTI173537,JapicCTI173678 and JapicCTI183855).
    • 06 Jan 2020 According to an Ono Pharmaceutical media release, company has submitted a new drug application ("NDA") for manufacturing and marketing approval for ONO-5704/SI-613 in Japan, for the treatment of osteoarthritis (knee joint, hip joint and ankle joint). The NDA is based on the results of three Phase III clinical studies conducted with the Product in Japan.
    • 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top